Filing Flows › C4 Therapeutics (CCCC) › Q3 2026
C4 Therapeutics (CCCC) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
C4 Therapeutics (CCCC) reported revenue of $8.5M for the third quarter 2026 (Q3 2026), -25% from a year earlier and +28% from the quarter before. Operating margin was -290.5%, net loss $21.8M (257.9% of revenue).
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.5M | +28% | -25% |
| Operating profit | −$24.6M | — | — |
| Net earnings | −$21.8M | — | — |
| Operating cash flow | −$26.0M | — | — |
What changed
Revenue was $8.5M in Q3 2026, down 25% year over year and up 28% from the previous quarter.
Operating costs exceeded revenue by $24.6M, an operating margin of -290.5%. Total costs fell 28% while revenue fell 25%. The quarter ended with a net loss of $21.8M, narrower than the previous quarter's $23.6M loss.
Operating cash flow was −$26.0M. Non-cash charges added back $320K of depreciation and $3.0M of share-based compensation. Working capital and other items used $7.4M.
Questions
What was C4 Therapeutics' revenue in the third quarter 2026?
C4 Therapeutics (CCCC) reported revenue of $8.5M for the third quarter 2026 (Q3 2026), -25% from a year earlier and +28% from the quarter before.
Was C4 Therapeutics profitable in the third quarter 2026?
Operating loss was $24.6M (-290.5% of revenue) and net loss $21.8M.
Source: C4 Therapeutics 10-Q on SEC EDGAR.